Cost-benefit rulings ahead at Germany's Gemeinsame Bundesausschuss:
This article was originally published in Clinica
Executive Summary
Germany's Gemeinsame Bundesausschuss (G-BA), the joint federal committee that decides whether healthcare products are reimbursable, used cost-benefit analysis for the first time this week in coming to a decision on genetically-engineered insulin analog. So reported FT Deutschland, of a decision that will resonate not just throughout the pharma sector, but will have implications for device manufacturers too. In declining reimbursement of the product for all but exceptional cases, the G-BA followed the 2004 recommendation of its executive arm, the IQWiG. Its decision effectively said that the benefits for type-2 diabetes sufferers do not match the euro30m ($38m) spent annually on the medication. It will now be used only when it is not more expensive than conventional human insulin (it is currently at a premium of 30-60%). There are 250,000 sufferers of type-2 diabetes in Germany. IQWiG will doubtless feel empowered by the public vindication of its decision; more evaluations (for asthma and high blood pressure, etc) lie ahead.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.